Literature DB >> 9515161

Induction of apoptosis by an inhibitor of cAMP-specific PDE in malignant murine carcinoma cells overexpressing PDE activity in comparison to their nonmalignant counterparts.

D Marko1, K Romanakis, H Zankl, G Fürstenberger, B Steinbauer, G Eisenbrand.   

Abstract

In order to study potential changes in phosphodiesterase (PDE) activity associated with malignant transformation, normal primary keratinocytes and cells corresponding to different stages of epidermal tumor development in mouse skin were analyzed with respect to their 3',5'-cyclic adenosine monophosphate (cAMP) hydrolyzing activity. Expression of cAMP-specific PDE-4, intracellular cAMP content, and the sensitivity to the growth inhibitory effect of the PDE-4-specific inhibitor 7-benzylamino-6-chloro-2 piperazino-4-pyrrolidino-pteridine (DC-TA-46) were studied in the two papilloma cell lines, MSCP6 and 308, and in the highly malignant carcinoma cell line CarB. No significant difference in soluble PDE activity and in intracellular cAMP was found in the two papilloma cell lines when compared to primary keratinocytes. In contrast, the spindle-cell carcinoma cell line CarB exhibited significantly higher PDE activity, concomitant with the lowest cAMP level. In all cell lines and also in the primary keratinocytes, rolipram-sensitive PDE-4 activity accounted for the major cAMP-hydrolyzing activity. In primary keratinocytes and in MSCP6 cells, the PDE-4 inhibitor DC-TA-46 induced at best marginal growth inhibition, whereas cell growth of 308 cells was markedly affected at concentrations > 2 microM. The carcinoma cell line CarB showed the highest sensitivity to DC-TA-46 (IC50 = 0.8 +/- 0.3 microM). Treatment of CarB cells with DC-TA-46 strongly inhibits intracellular PDE activity, resulting in a marked and long-lasting rise of cAMP. After 24 h of treatment, arrest in the G0/G1 phase of the cell cycle is induced. Treatment with concentrations > 2 microM of this highly effective PDE inhibitor results in induction of apoptotic cell death, as detected by fluorescence microscopy, flow cytometry, and ELISA-based determination of fragmented DNA in intact cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9515161     DOI: 10.1007/BF02737806

Source DB:  PubMed          Journal:  Cell Biochem Biophys        ISSN: 1085-9195            Impact factor:   2.194


  18 in total

1.  Inhibition of phosphodiestrase 9 induces cGMP accumulation and apoptosis in human breast cancer cell lines, MCF-7 and MDA-MB-468.

Authors:  R Saravani; F Karami-Tehrani; M Hashemi; M Aghaei; R Edalat
Journal:  Cell Prolif       Date:  2012-04-02       Impact factor: 6.831

Review 2.  Advances in targeting cyclic nucleotide phosphodiesterases.

Authors:  Donald H Maurice; Hengming Ke; Faiyaz Ahmad; Yousheng Wang; Jay Chung; Vincent C Manganiello
Journal:  Nat Rev Drug Discov       Date:  2014-04       Impact factor: 84.694

3.  Glial restricted precursor cell transplant with cyclic adenosine monophosphate improved some autonomic functions but resulted in a reduced graft size after spinal cord contusion injury in rats.

Authors:  Yvette S Nout; Esther Culp; Markus H Schmidt; C Amy Tovar; Christoph Pröschel; Margot Mayer-Pröschel; Mark D Noble; Michael S Beattie; Jacqueline C Bresnahan
Journal:  Exp Neurol       Date:  2010-10-30       Impact factor: 5.330

4.  Cyclic AMP specific phosphodiesterase activity and colon cancer cell motility.

Authors:  K Murata; T Sudo; M Kameyama; H Fukuoka; M Muka; Y Doki; Y Sasaki; O Ishikawa; Y Kimura; S Imaoka
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

Review 5.  Clinical and molecular genetics of the phosphodiesterases (PDEs).

Authors:  Monalisa F Azevedo; Fabio R Faucz; Eirini Bimpaki; Anelia Horvath; Isaac Levy; Rodrigo B de Alexandre; Faiyaz Ahmad; Vincent Manganiello; Constantine A Stratakis
Journal:  Endocr Rev       Date:  2013-12-05       Impact factor: 19.871

6.  Harnessing protein kinase A activation to induce mesenchymal-epithelial programs to eliminate chemoresistant, tumor-initiating breast cancer cells.

Authors:  Alex J Gooding; William P Schiemann
Journal:  Transl Cancer Res       Date:  2016-08       Impact factor: 1.241

7.  In vitro and in vivo inhibition of SK-N-MC neuroblastoma growth using cyclic nucleotide phosphodiesterase inhibitors.

Authors:  M Giorgi; C Leonetti; G Citro; G Augusti-Tocco
Journal:  J Neurooncol       Date:  2001-01       Impact factor: 4.130

Review 8.  Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets.

Authors:  F Ahmad; T Murata; K Shimizu; E Degerman; D Maurice; V Manganiello
Journal:  Oral Dis       Date:  2014-09-12       Impact factor: 3.511

9.  Inhibitory effects of quercetin derivatives on phosphodiesterase isozymes and high-affinity [(3) H]-rolipram binding in guinea pig tissues.

Authors:  Agnes L-F Chan; Hui-Lin Huang; Hui-Chi Chien; Chi-Ming Chen; Chun-Nan Lin; Wun-Chang Ko
Journal:  Invest New Drugs       Date:  2008-02-09       Impact factor: 3.850

10.  Cyclic AMP induces apoptosis in multiple myeloma cells and inhibits tumor development in a mouse myeloma model.

Authors:  Virginie Follin-Arbelet; Peter O Hofgaard; Harald Hauglin; Soheil Naderi; Anders Sundan; Rune Blomhoff; Bjarne Bogen; Heidi K Blomhoff
Journal:  BMC Cancer       Date:  2011-07-18       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.